|
4basebio PLC - Cambridge, England-based life sciences company - Appoints mRNA biology and translation specialist Jeff Coller to its Strategic Advisory Board. Coller’s expertise will assist with the company’s efforts to reshape the scalable manufacturing of next-generation nucleic acid therapeutics. Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University and the Inaugural Director of the RNA Innovation Center. ‘Jeff’s groundbreaking discoveries in mRNA stability and translation are nothing short of transformative for our industry. His vision aligns perfectly with 4basebio‘s bold mission to dismantle the bottlenecks of traditional manufacturing. With Jeff on our Strategic Advisory Board, we are supercharging our ability to deliver the highest-performing synthetic DNA platforms to our partners - faster, purer, and built for the future of genetic medicine,’ says Chief Executive Amy Walker. Current stock price: 540.00 pence 12-month change: down 45% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
